Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Bosses Resign At Japan Health Supplement Firm Probing Deaths

The chairman and president of a major Japanese dietary supplement maker announced their resignation on Tuesday, as the company probes dozens of deaths potentially linked to products meant to lower cholesterol.

International Business Times

Dear Pharmac – do things differently: what David Seymour’s expectations could mean for the drug-buying agency

Associate Health Minister David Seymour’s recent letter of expectations to drug buying agency Pharmac could fundamentally change the way the organisation makes decisions. Some of these changes could also make Pharmac’s job harder and its decisions more unpopular.

The Conversation

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

The Guardian - US

From analysis to the latest developments in health,
read the most diverse news in one place.

UN Urges Gilead To 'Make History' With Game-changing HIV Drug

Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat…

International Business Times

3 Healthcare Stocks With High Profit Margins

With an aging population, increasing drug demand, and the development of advanced technologies, the healthcare industry is booming. Thus, it could be wise to invest in fundamentally sound healthcare stocks, Veeva Systems (VEEV), Align Technology (ALGN), and Medpace Holdings (MEDP), which have high-profit margins. Read on.

StockNews.com

3 Pharmaceutical Stocks With Strong Pipelines

The pharmaceutical industry is flourishing due to increasing medical demands and rising healthcare spending worldwide. Hence, pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck & Co. (MRK), with strong pipelines, might be worth buying. Read more….

StockNews.com

Shanghai Composite Index Ended Nearly Flat on Friday

Shenzhen Component Index closed down 0.18%

Caixin Global

Read news from The Economist, FT, and more,
with one subscription

The threat of litigation looms as Purdue Pharma returns to settlement talks

OxyContin maker Purdue Pharma, the family that owns it and lawyers for thousands of parties with claims against it are getting ready to work on a new settlement after the U.S. Supreme Court rejected the last one

The Independent UK

South Africa drops probe of J&J after it agrees to lower price of TB drug and withdraws patent

Medical advocacy groups welcomed Johnson & Johnson’s decision not to enforce its patent on a critical tuberculosis medication, allowing its production at much lower prices, after South African authorities opened an investigation into the conglomerate

The Independent UK

London biotech secures £90 million backing

Myricx Bio’s £90 million Series A fundraising will initially focus on developing its work treating solid tumours, such as breast and gastric cancers, but potentially can apply across all cancers

Evening Standard

3 Mid-Cap Stocks Analysts Believe Will Soar 50% or More

The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…

StockNews.com

US Supreme Court Rejects Opioid Settlement That Shields Sackler Family

The US Supreme Court on Thursday rejected Purdue Pharma's $6 billion opioids settlement immunizing the Sackler family, which controlled the drugmaker, from future litigation.

International Business Times

Walgreens will close a ‘significant’ number of failing stores across US

There are 8,500 Walgreens stores across the country, and around a quarter are failing

The Independent UK

Supreme Court rejects settlement with OxyContin maker Purdue Pharma over legal protections for the Sackler family that owned the company

The Supreme Court ruled 5-4 against an estimated US$6 billion Purdue Pharma bankruptcy plan on June 27, 2024, that would have shielded the Sackler family – which owned and controlled the company – from legal liability.

The Conversation

Get all your
news in one place.

100's of premium titles.
One news app.

France 24

US Supreme Court rejects $6 billion OxyContin settlement shielding Sackler family

The US Supreme Court on Thursday rejected OxyContin maker Purdue Pharma's $6 billion settlement that would have shielded the Sackler family, who owned the company and earned tens of billions as it flooded the country with the highly addictive drug, from future civil lawsuits over the role they played in…

The Independent UK

The legal odyssey for OxyContin maker Purdue Pharma and its owners is complex. Here's what to know

The Supreme Court has rejected a settlement for OxyContin maker Purdue Pharma and members of the Sackler family who own the company

The Independent UK

Supreme Court shreds nationwide $6 billion opioid settlement plan in ruling against Sackler family

The Supreme Court said the Sackler family cannot use a Chapter 11 reorganization plan to protect themselves from civil liability

The Guardian - US

US supreme court blocks Purdue Pharma’s bankruptcy settlement that would shield Sacklers from lawsuits

Controversial deal would have protected billionaire family owners from further liability over US opioid epidemic

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Walgreens to take a hard look at underperforming stores, could shutter hundreds more

Walgreens is finalizing a plan to fix its business that could result in the closure of hundreds of additional stores in the next three years

The Independent UK

The Supreme Court rejects a nationwide opioid settlement with OxyContin maker Purdue Pharma

The Supreme Court has rejected a nationwide settlement with OxyContin maker Purdue Pharma that would've shielded Sackler family members who own the company from civil lawsuits over the toll of opioids but also would've provided billions of dollars to combat the epidemic

Tom’s Hardware

Organ-on-chip market for drug testing expected to see tenfold growth to $1.3 billion by 2032

Pharmaceutical and cosmetic companies are the number one consumers of this tech, but other industries are taking notice.

The Guardian - UK

Ozempic maker Novo Nordisk invests $4bn to meet US ‘skinny jab’ demand

Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product Wegovy

The Guardian - AU

Pharmacists say they were not consulted on ‘rushed’ Labor-Greens vape deal

Federal health minister counters that Pharmacy Guild did not make submission to regulation inquiry and selling vapes still a decision for individual stores

Kiplinger

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

Tom’s Hardware

AMD's Strix Halo being tested with 128GB RAM — shipping records reveal more about extreme 120W APU

AMD's upcoming Strix Halo APU, never confirmed but seen in shipping records and other leaks, has been spotted again in trade data: now with 128GB of RAM and 120W TDP.

1 … 33 34 35 36

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.